Abstract:Background & aims: Previous research established that the availability of L-arginine affects placental vascular development and fetal growth. However, practical details associated with the effects of L-arginine supplementation on the neonatal outcomes of hypertensive disorder (HD) and intrauterine growth restriction (IUGR) pregnancies are limited. Methods: The PubMed, ScienceDirect, and Web of Science databases were searched for peer-reviewed literature published by September 30, 2021 to investigate the operational details of L-arginine supplementation in improving neonatal outcomes in complicated pregnancies. Standardized mean difference (SMD) and weighted mean difference (WMD) of continuous variables, as well as the risk ratio (RR) for categorical variables were pooled by random-effects models. Results: The results indicated that L-arginine supplementation increased the plasma nitric oxide (NO) concentrations in IUGR pregnancies (SMD: 0.71; 95% CI: 0.45, 0.97; I-2 = 0%), but decreased the risk of preeclampsia in HD mothers (RR: 0.49; 95% CI: 0.31, 0.76; I-2 = 0%). Administration with L-arginine elevated birth weights both in hypertensive and IUGR pregnant women, with WMDs of 194.70 g (95% CI: 58.21, 331.20; I-2 = 44.2%) and 134.00 g (95% CI: 43.53, 224.46; I-2 = 42.4%), respectively. However, the intervention had no effect on gestational age except in HD pregnancies (WMD: 7.05 d; 95% CI: 3.16, 10.95; I-2 = 36.5%). L-arginine administration during pregnancy significantly reduced the small for gestational age (SGA) risk of fetus both in HD (RR: 0.51; 95% CI: 0.31, 0.83; I-2 = 0.0%) and IUGR mothers (RR: 0.46; 95% CI: 0.25, 0.88; I-2 = 0.0%). Subgroup analyses revealed that L-arginine supplementation at <4 g/ d dosage or for >1-month duration or in the third trimester had a greater effect on birth weights in HD women without proteinuria, but a higher L-arginine dosage was more beneficial for extending gestational age and reducing the risk of SGA in older pregnancies. Additionally, intravenous infusion of L-arginine, but not oral administration, significantly increased birth weight in IUGR pregnancies with elevated NO concentrations, although the recommended amount should be confined to <4 g/d. Conclusions: These findings provide practical guidelines for L-arginine supplementation to improve the birth outcomes of complicated pregnancies. Registry number: CRD42021246290 (https://www.crd.york.ac.uk/PROSPERO). (C) 2022 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Effects of Arginine on NO and Microvessels of Uteroplacenta in Mice

L-arginine supplementation improved neonatal outcomes in pregnancies with hypertensive disorder or intrauterine growth restriction: A systematic review and meta-analysis of randomized controlled trials

Effect of L-arginine on Blood Physiological Parameters of Pregnancy Mouse

Arginine bioavailability and endothelin-1 system in the regulation of vascular function of umbilical vein endothelial cells from intrauterine growth restricted newborns.

Effect of L-arginine on nitric oxide levels of maternal and neonatal umbilical blood in intrauterine growth retardation

Comparison of Diagnostic Values of Maternal Arginine Concentration for Different Pregnancy Complications: A Systematic Review and Meta-Analysis

Effects of Arginine and Vera Pammy on the Development of Intrauterine Growth Retardation in Fetal Mouses

Effects of supplement of arginine on anti-oxidation and arginine metabolism in intrauterine growth retardation piglets

Effect of L-arginine Treatment on Fetal Umbilical Artery Flow in Intrauterine Growth Retardation

Impacts of arginine nutrition on embryonic and fetal development in mammals

The Effects and Mechanism of L-arginine Treatment on Fetal Growth Restriction

[An Experimental Study on the Treatment of Fetal Rabbits with Intrauterine Growth Retardation].

Dietary supplementation with L-arginine between days 14 and 25 of gestation enhances NO and polyamine syntheses and the expression of angiogenic proteins in porcine placentae

Arginine Regulates the Negative Effect of Intrauterine Growth Retardation by Increasing Mucosal mTOR Signal in Neonatal Pigs

Effects of Dietary L-Arginine and N-Carbamylglutamate Supplementation on Intestinal Integrity, Immune Function, and Oxidative Status in Intrauterine-Growth-Retarded Suckling Lambs

Dietary N-carbamylglutamate or L-arginine Improves Fetal Intestinal Amino Acid Profiles During Intrauterine Growth Restriction in Undernourished Ewes

Effect of Dietary Arginine and N-carbamoylglutamate Supplementation on Reproduction and Gene Expression of Enos, VEGFA and PlGF1 in Placenta in Late Pregnancy of Sows.

Dietary Rumen-Protected L-arginine or N-carbamylglutamate Enhances Placental Amino Acid Transport and Suppresses Angiogenesis and Steroid Anabolism in Underfed Pregnant Ewes.

Analysis of placental vascularization in a pharmacological rabbit model of IUGR induced by L-NAME, a nitric oxide synthase inhibitor

Dietary Arginine Supplementation During Early Pregnancy Enhances Embryonic Survival in Rats.

Effects of Different Levels of Dietary L-Arg on Reproductive Performance and Blood Biochemical Indexes of Pregnant Sows